Date: 2013-12-02
Type of information: Distribution agreement
Compound: ConfirmMDx for Prostate Cancer
Company: MDX Health (Belgium) HealthSmart (USA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment.
Disease: prostate cancer
Details: * On December 2, 2013, MDxHealth, a Belgian molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has announced that it has signed agreements with HealthSmart, a Preferred Provider Organization (PPO) network to provide their members access to the ConfirmMDx® for Prostate Cancer test.
Financial terms:
Latest news:
